Peptides DB
Research-centric peptide and protocol reference hub
Study 30 of 33Tirzepatide literatureBiomacromolecules2026

Ensemble-Based Segmental Helical Organization in an Aib-Rich Lipidated Peptide: Biomacromolecular Insights from High-Field NMR.

Tirzepatide exists as a conformational ensemble in solution, with both locally ordered and flexible regions, but clinical implications are not addressed.

Read at BiomacromoleculesAdd to compare

Where it sits

this study against the rest of the tirzepatide corpus
4
Preclinical · this one
21
Observational
1
Open-label
4
Randomised
3
Reviews

Summary and findings

This study investigated the solution conformation of tirzepatide using NMR spectroscopy. It focused on residue-specific resonance assignments and conformational properties in an aqueous solution. The findings suggest that tirzepatide exists as a conformational ensemble with locally ordered and flexible regions.

How much of this paper we could read: full text read (0.70). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Not reported in abstract.2026

Abstract

The authors’ words, as Biomacromolecules supplied them

Tirzepatide (TZP) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that has demonstrated remarkable therapeutic efficacy for the treatment of type 2 diabetes and obesity. Despite its clinical importance, residue-specific information on its solution conformation remains limited due to its structural complexity, including noncanonical amino acids and a lipidated side chain. In this study, we performed a solution NMR investigation of tirzepatide to establish residue-specific resonance assignments and characterize its conformational properties in an aqueous solution. Backbone and side-chain resonances were assigned using multidimensional NMR spectroscopy, including 1H-15N HMQC, TOCSY, and NOESY experiments. Reliable sequential NOE connectivities were identified for several peptide segments, while ambiguous and unresolved resonances were conservatively excluded from the structural interpretation. The N-terminal Aib2 residue served as an important assignment anchor but did not define a stable terminal structure. In contrast, the Aib13 region exhibited a locally organized backbone environment with a short helical-like conformational tendency, suggesting Aib13-centered local ordering within the peptide chain. Structure calculations based on the 1.2 GHz NMR and CD experiments revealed that tirzepatide does not adopt a single rigid conformation in solution but instead exists as a conformational ensemble composed of locally ordered and flexible regions. These findings provide a residue-specific view of tirzepatide dynamics in solution and offer structural insights into the conformational landscape of this therapeutically important peptide.

Background

Not reported in abstract.

Methods

Not reported in abstract.

Results

Not reported in abstract.

Interpretation

Not reported in abstract.

Limitations

Not reported in abstract.

Elsewhere in the Tirzepatide corpus

BCardiovascular outcomes with semaglutide versus tirzepatide in patients with obesity and atherosclerotic cardiovascular disease without diabetes.American heart journal plus : cardiology research and practice · 2026 · n=11330 · 19.5% 5-point MACE for semaglutide vs 17.1% for tirzepatide, HR 1.03, 95% CI 0.94-1.12.HumanAIxekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial.Arthritis & rheumatology (Hoboken, N.J.) · 2026 · 31.7% IXE + TZP vs 0.8% IXE alone at 36 weeks, P<0.001.HumanBTirzepatide Versus Conventional Glucagon-Like Peptide-1 Receptor Agonists for Treatment Simplification in Type 2 Diabetes Mellitus: A Real-World Study.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2026 · Odds ratio: 3.69, 95% confidence interval: 2.21-6.16; P < .001.HumanB12-month weight-loss trajectories and predictors of response to tirzepatide under individualized dosing: A multicenter real-world study.Obesity pillars · 2026 · n=249 · Mean weight loss was 19.9 ± 8.6% at 12 months.HumanBReal-world, digital-first delivery of GLP-1 receptor agonist therapy in women.Nature medicine · 2026 · Mean weight reduction was 16.1 kg (95% CI 15.9 to 16.2; P < 0.001).HumanAEvaluation of clinical relevance of weight nadirs and weight regain during 3 years of treatment with tirzepatide in participants with obesity or overweight and prediabetes.Obesity pillars · 2026 · Mean weight regain from nadir to Week 176 was 3.8 kg for 5 mg, 4.4 kg for 10 mg, and 3.7 kg for 15 mg.Human